LCH-IV, International Collaborative Treatment Protocol for barn og ungdom med Langerhans cellehistiocytose
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The international efforts of the past 20 years have shown that combination therapy with vinblastine and prednisone is an effective therapy for Multi-system (MS)-LCH. The previous prospective trial LCH-III confirmed this regimen as a standard regimen for MS-LCH in patients with and without risk organ involvement. It also showed that prolonged treatment in the latter group (treatment duration of 12 vs. 6 months) is superior in preventing disease reactivations. The results of this trial are encouraging and serve as a basis for the LCH-IV study design.Due to the complexity of the disease presentations and outcomes, the LCH-IV study seeks to tailor treatment based on features at presentation and on response to treatment, leading to seven strata:
- Stratum I: First-line treatment for MS-LCH patients (Group 1) and patients with Single system (SS)-LCH with multifocal bone or "Central Nervous System (CNS)-risk" lesions (Group 2)
- Stratum II: Second-line treatment for non-risk patients (patients without risk organ involvement who fail first-line therapy or have a reactivation after completion of first-line therapy)
- Stratum III: Salvage treatment for risk LCH (patients with dysfunction of risk organs who fail first-line therapy)
- Stratum IV: Stem cell transplantation for risk LCH (patients with dysfunction of risk organs who fail first-line therapy)
- Stratum V: Monitoring and treatment of isolated tumorous and neurodegenerative CNS-LCH
- Stratum VI: Natural history and management of "other" SS-LCH (patients who do not need systemic therapy at the time of diagnosis)
- Stratum VII: Long-term Follow up (all patients irrespective of previous therapy will be followed for reactivation or permanent consequences once complete disease resolution has been achieved and the respective protocol treatment completed)
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Children's of Alabama
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85006
- Phoenix Children's Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72202
- Arkansas Children's Hospital
-
-
California
-
Los Angeles, California, Forente stater, 90027
- Children's Hospital of Los Angeles
-
Madera, California, Forente stater, 93636
- Valley Children's Healthcare
-
Oakland, California, Forente stater, 94609
- UCSF Benioff Children's Hospital of Oakland
-
Orange, California, Forente stater, 92868
- Children's Hospital of Orange County
-
San Francisco, California, Forente stater, 94158-0106
- UCSF Helen Diller Family Cancer Center
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06106
- Connecticut Children's Medical Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Children's National Medical Center
-
-
Florida
-
St. Petersburg, Florida, Forente stater, 33701
- Johns Hopkins All Children's Hospital
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30342
- Children's Healthcare of Atlanta, Emory
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611-2991
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Riley Hospital for Children - Indiana University
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 64108
- Children's Mercy Hospitals
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- University of Kentucky A.B.Chandler Medical Center
-
Louisville, Kentucky, Forente stater, 40202
- University of Louisville, Norton Children's Hospital
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Forente stater, 02115
- Dana Farber Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55404
- Children's Minnesota
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Hackensack University Medical Center
-
-
New York
-
New Hyde Park, New York, Forente stater, 11040
- Cohen Children's Medical Center
-
New York, New York, Forente stater, 10029
- Mount Sinai Hospital
-
New York, New York, Forente stater, 10032
- Columbia University / Herbert Irving Cancer Center
-
New York, New York, Forente stater, 10170
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, Forente stater, 13210
- SUNY Upstate Medical University
-
The Bronx, New York, Forente stater, 10467
- Children's Hospital at Montefiore
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28203
- Carolinas Medical Center, Levine Children's Hospital
-
-
Ohio
-
Akron, Ohio, Forente stater, 44308
- Akron Children's Hospital
-
Cincinnati, Ohio, Forente stater, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Forente stater, 44106
- Rainbow Babies & Children's Hospital, University Hospitals
-
Toledo, Ohio, Forente stater, 43606
- Russell J Ebeid Children's Hospital (Promedica)
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina (MUSC)
-
Greenville, South Carolina, Forente stater, 29605
- Greenville Health System BI-LO Charities Children's Cancer Center
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38105
- St. Jude Children's Research Hospital
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Forente stater, 75235
- Children's Medical Center Dallas, UT Southwestern
-
-
Washington
-
Spokane, Washington, Forente stater, 99204
- Providence Sacred Heart Children's Hospital
-
Tacoma, Washington, Forente stater, 98431
- Madigan Army Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- American Family Children's Hospital University of Wisconsin
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Stratum I
- Patients must be less than 18 years of age at the time of diagnosis.
- Patients must have histological verification of the diagnosis of Langerhans cell histiocytosis according to the criteria described in Section 6.1
- Signed informed consent form
-
Stratum II
- Patients of Stratum I who have:
- Progressive disease (AD worse) in non-risk organs after 6 weeks (Initial Course
- AD intermediate or worse in non-risk organs or AD better in risk organs after 12 weeks (Initial Course 2)
- Disease progression (AD worse) in non-risk organs at any time during continuation treatment
- Active disease at the end of Stratum I treatment
- Disease reactivation in non-risk organs at any time after completion of Stratum I treatment
-
Stratum III
-
Patients from Stratum I who fulfill the following criteria:
-
AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD intermediate in risk organs after week 12 (after Initial Course 2).
-
Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as
- Hb <70 g/L (<7.0 g/dl) and/or transfusion dependency
- PLT <20 x109/L (20,000/μL) and/or transfusion dependency (both criteria have to be fulfilled) AND/OR
- Liver dysfunction (or digestive involvement with protein loss)
- Total protein <55 g/L or substitution dependency
- Albumin <25 g/L or substitution dependency (at least one of the two criteria to be fulfilled)
-
-
Stratum IV
- Patients from Stratum I or Stratum III who fulfill the following criteria:
- AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD intermediate in risk organs after week 12 (after Initial Course 2) of Stratum I OR
- AD worse after the 2nd and 3rd 2-CdA/Ara-C course, and those AD worse or AD intermediate after the 4th 2-CdA/Ara-C course of Stratum III AND
- Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as defined in Table XI (see Section 10.3.1).
- Informed consent: All patients or their legal guardians (if the patient is <18 years of age) must sign an Ethics or institutional Review Board approved consent form indicating their awareness of the investigational nature and the risks of this study. When appropriate, younger patients will be included in all discussions in order to obtain assent.
- Adequate organ function: Patients should have adequate hepatic, renal, cardiac and pulmonary function to undergo reduced intensity HCT based upon local institutional guidelines, or at a minimum meet requirements noted in eligibility checklist Appendix A-VIII_1. However, significant hepatic and pulmonary dysfunction, if secondary to underlying LCH disease activity, will not exclude patients from protocol enrollment and should be discussed with the National PI Coordinator and the Coordinating Principal Investigator.
-
Stratum V
- All patients with verified diagnosis of LCH and MRI findings consistent with ND-CNSLCH irrespective of previous treatments (also those not registered to other Strata ofLCH-IV).
- Patients with isolated tumorous CNS-LCH (including isolated DI with mass lesion in the hypothalamus-pituitary axis). In patients with already established diagnosis of LCH and radiologic finding of CNS lesions compatible with LCH, a biopsy of the lesion is not obligatory. In all other cases a biopsy of the lesion is needed for inclusion into the study
-
Stratum VI
-- Patients with newly diagnosed SS-LCH and localization other than "multifocal bone",isolated tumorous CNS lesion, or isolated "CNS-risk" lesion.
-
Stratum VII -- All patients registered in LCH IV (regardless of treatment) as long as consent for longterm follow-up has not been withheld.
Exclusion Criteria:
-
Stratum I
- Pregnancy (patients of child-bearing age must be appropriately tested before chemotherapy)
- LCH-related permanent consequences (e.g. vertebra plana, sclerosing cholangitis, lung fibrosis, etc.) in the absence of active disease
- Prior systemic therapy
-
Stratum II
- Patients with progressive disease in risk organs
- Permanent consequences (e.g. sclerosing cholangitis, lung fibrosis, etc.) without evidence of active LCH in the same organ or in any other locations
- No written consent of the patient or his/her parents or legal guardian
-
Stratum III
- The presence of any of the following criteria will exclude the patient from the study:
- Isolated sclerosing cholangitis without evidence of active hepatic LCH as the only evidence of risk organ involvement.
- Inadequate renal function as defined by serum creatinine > 3x normal for age
-
Stratum IV
- Pulmonary failure (requiring mechanical ventilation) not due to active LCH.
- Isolated liver sclerosis or pulmonary fibrosis, without active LCH.
- Uncontrolled active life-threatening infection.
- Decreased renal function with a GFR of less than 50ml/1.73m2/min.
- Pregnancy or active breast feeding
- Failure to provide signed informed consent
-
Stratum VI
- Patients with SS-LCH who have an isolated tumorous CNS lesion (they are eligible for Stratum V),
- Patients with isolated "CNS-risk" or multifocal bone lesions (they are eligible for Stratum I, Group 2)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Stratum I
Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV). Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences. |
Stratum I Stratum I
Andre navn:
Stratum I
Andre navn:
|
|
Eksperimentell: Stratum II
A uniform "intensive" 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms "INDOMETHACIN" and "6-MP/MTX" (mercaptopurine and Methotrexate). |
Andre navn:
Stratum I Stratum I
Andre navn:
Stratum I
Andre navn:
Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months. fixed dose weekly orally for total treatment duration of 24 months. |
|
Eksperimentell: Stratum III
Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy. The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum. |
Andre navn:
|
|
Eksperimentell: Stratum IV
To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III). |
|
|
Eksperimentell: Stratum V
Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH - Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice. |
Andre navn:
Andre navn:
Andre navn:
|
|
Eksperimentell: Stratum VI
Natural history and management of "other" SS-LCH not eligible for stratum I group 2.
|
Andre navn:
Andre navn:
Andre navn:
Stratum I Stratum I
Andre navn:
Stratum I
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Patients with Reactivation Free Survival
Tidsramme: 12 Months
|
Stratum I, II, VI |
12 Months
|
|
Response Rate of Second Cycle
Tidsramme: 9 weeks
|
Stratum III |
9 weeks
|
|
Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)
Tidsramme: 3 Years
|
Stratum IV |
3 Years
|
|
The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesions
Tidsramme: 2 Years
|
Stratum V |
2 Years
|
|
The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCH
Tidsramme: 2 Years
|
Stratum V |
2 Years
|
|
Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.
Tidsramme: 2 Years
|
From all treatment stratum via long-term follow up in Stratum VII |
2 Years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall deltakere med alvorlige og ikke-alvorlige uønskede hendelser
Tidsramme: 2 år
|
2 år
|
|
|
Kumulativ forekomst av reaktiveringer i risikoorganer
Tidsramme: 2 år
|
2 år
|
|
|
Forekomst av hematopoetisk utvinning og donorkimerisme ved d+100 og 1 år etter RIC-HSCT
Tidsramme: 2 år
|
2 år
|
|
|
Identifisere mulige risikofaktorer for permanente konsekvenser (PC)
Tidsramme: 2 år
|
2 år
|
|
|
Overall Survival
Tidsramme: 2 Years
|
Stratum I |
2 Years
|
|
Incidence of Permanent Consequences
Tidsramme: 2 Years
|
All Stratum |
2 Years
|
|
Time to complete disease resolution
Tidsramme: 2 Years
|
Stratum III |
2 Years
|
|
Response rate to the combination of prednisone, vincristine and cytarabine
Tidsramme: 2 years
|
Stratum II |
2 years
|
|
The proportion of patients alive and free of disease without permanent consequences (e.g. diabetes insipidus, anterior pituitary dysfunction, radiological or clinical neurodegeneration)
Tidsramme: 2 Years
|
Stratum II |
2 Years
|
|
Percentage of treatment-related toxicities
Tidsramme: 2 Years
|
Stratum II |
2 Years
|
|
Reactivation rates after continuation treatment with Indomethacin vs. 6-MP/MTX.
Tidsramme: 2 years
|
Stratum II |
2 years
|
|
The type of subsequent intensive and/or maintenance therapy utilized
Tidsramme: 2 Years
|
Stratum III |
2 Years
|
|
Early and late mortality
Tidsramme: 2 Years
|
Stratum II |
2 Years
|
|
Early and late toxicity
Tidsramme: 2 Years
|
Stratum III |
2 Years
|
|
d+100 transplant related mortality
Tidsramme: 2 Years
|
Stratum IV |
2 Years
|
|
Record all occurrence of skin, GI or liver abnormalities fulfilling criteria of Grades II-IV acute GVHD
Tidsramme: 2 Years
|
Stratum IV: Hematopoetic Stem Cell Transplantation for Risk LCH |
2 Years
|
|
Percentage of Participants with incidence of chronic GVHD
Tidsramme: 2 Years
|
Stratum IV |
2 Years
|
|
Response Rate to ND-CNS-targeted therapy at 12 and 24 months after start of therapy
Tidsramme: 2 years
|
Stratum V |
2 years
|
|
Response of isolated tumorous CNS-LCH to 2-CDA
Tidsramme: 2 Years
|
Stratum V |
2 Years
|
|
Frequency of ND-CNS-LCH in patients with isolated tumorous CNS-LCH
Tidsramme: 2 Years
|
Stratum V |
2 Years
|
|
Methods of early identification of ND-CNS-LCH
Tidsramme: 2 Years
|
Stratum V - Exploration of the value of neurochemistry, neurophysiology, and neuropsychology methods in early identification of ND-CNS-LCH and in assessing its severity, and comparison to MRI findings. |
2 Years
|
|
Need for systemic therapy later during disease course
Tidsramme: 2 Years
|
Stratum VI |
2 Years
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Milen Minkov, MD, Ph.D, Children's Cancer Research Institute / St. Anna Children's Hospital
- Studiestol: Carlos Rodriguez-Galindo, MD, North American Consortium for Histiocytosis
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i luftveiene
- Lungesykdommer
- Lymfesykdommer
- Lungesykdommer, interstitielle
- Histiocytose
- Hemic og lymfatiske sykdommer
- Histiocytose, Langerhans-celle
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Terapeutikk
- Kirurgiske prosedyrer, operativ
- Nukleinsyrer, nukleotider og nukleosider
- Alkaloider
- Polysykliske forbindelser
- Transplantasjon
- Indoler
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Puriner
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Gravadienes
- Gravaner
- Steroider
- Smeltede ringforbindelser
- Nukleosider
- Ribonukleosider
- Pteriner
- Pteridiner
- Gravadienedioler
- Vinca -alkaloider
- Secologanin tryptaminalkaloider
- Indolalkaloider
- Indolizidiner
- Indolisiner
- Arabinonukleosider
- Aminopterin
- Immunoglobulinisotyper
- Immunoglobulin G.
- Celletransplantasjon
- Celle- og vevsbasert terapi
- Biologisk terapi
- Deoxyribonucleosides
- Stamcelletransplantasjon
- 2-kloradenosin
- Adenosin
- Purin nukleosider
- Deoxyadenosines
- Sulfhydrylforbindelser
- Metotreksat
- Prednison
- Cytarabin
- Merkaptopurin
- Vinblastin
- Immunglobuliner, intravenøst
- Kladribin
- Indometacin
- Hematopoietisk stamcelletransplantasjon
Andre studie-ID-numre
- 13-428
- 2011-001699-20 (EudraCT-nummer)
- 042011 (Annen identifikator: Children's Cancer Research Institute)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .